Global Bio CMO Market: Size, Trends & Forecasts (2018-2022)
Scope of the Report
The report entitled “Global Bio CMO Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the global biologics market by value, by top selling products, etc.
Growth of the overall global bio CMO market has been forecasted for the years 2017-2022, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.
Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics are key companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Pharmaceutical industry comprise of discovering, developing, producing and marketing of drugs for medical use. World’s largest pharmaceutical firms are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be divided into small molecule or conventional drugs and large molecule or biologic drugs.
Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. Biologics are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.
CMO or Contract Manufacturing Organization is a third party, which the pharmaceutical firms approach for the manufacturing of components of its product or whole of its product. Bio CMOs are typically used to provide secondary manufacturing coverage for the branded pharmaceutical industry. On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.
The global bio CMO market is expected to increase at a significant growth rate during the forecasted period (2017-2022). The global bio CMO market is supported by various growth drivers, such as increase in pharmaceutical industry, growth in use of biosimilars, potential biologics blockbusters, introduction of targeted therapins, grater outsourcing demand from global pharmas, etc. Yet, the market faces certain challenges, such as risk associated with CMOs, presence of in-house manufacturing facilities of big pharma companies, productivity issues with mammalian cell system, etc.